Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 29, Number 3—March 2023
Research

Comparative Effectiveness of COVID-19 Vaccines in Preventing Infections and Disease Progression from SARS-CoV-2 Omicron BA.5 and BA.2, Portugal

Irina Kislaya1Comments to Author , Pedro Casaca1, Vítor Borges, Carlos Sousa, Bibiana I. Ferreira, Ana Fonte, Eugénia Fernandes, Carlos Matias Dias, Sílvia Duarte, José Pedro Almeida, Inês Grenho, Luís Coelho, Rita Ferreira, Patrícia Pita Ferreira, Cláudia Medeiros Borges, Joana Isidro, Miguel Pinto, Luís Menezes, Daniel Sobral, Alexandra Nunes, Daniela Santos, António Maia Gonçalves, Luís Vieira, João Paulo Gomes, Pedro Pinto Leite, Baltazar Nunes, Ausenda Machado2, and André Peralta-Santos2
Author affiliations: Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal (I. Kislaya, V. Borges, C. Matias Dias, S. Duarte, L. Coelho, R. Ferreira, J. Isidro, M. Pinto, D. Sobral, A. Nunes, D. Santos, L. Vieira, J.P. Gomes, B. Nunes, A. Machado); Comprehensive Health Research Centre, Lisbon (I. Kislaya, C. Matias Dias, B. Nunes, A. Machado, A. Peralta-Santos); Direção-Geral da Saúde, Lisbon (P. Casaca, E. Fernandes, P. Pita Ferreira, P. Pinto Leite, A. Peralta-Santos); Unilabs, Porto, Portugal (C. Sousa, J.P. Almeida, L. Menezes, A. Maia Gonçalves); Algarve Biomedical Center Research Institute, Faro, Portugal (B.I. Ferreira, I. Grenho); Administração Central do Sistema de Saúde, Lisbon (A. Fonte, C.M. Borges)

Main Article

Table 1

Sociodemographic and clinical characteristics of COVID-19 case-patients in the study sample, by SARS-CoV-2 variant, Portugal, April 25–June 10, 2022

Characteristic No. (%) patients
BA.5, n = 12,306
 BA.2, n = 15,396
Sex
F 7,176 (58.3) 9,043 (58.7)
M
 5,130 (41.7)
 6,353 (41.3)
Age group, y
18–29 3,474 (28.2) 3,299 (21.4)
30–39 2,059 (16.7) 2,922 (19.0)
40–49 2,475 (20.1) 3,431 (22.3)
50–59 1,974 (16.0) 2,581 (16.8)
60–69 1,089 (8.9) 1,567 (10.2)
>70
 1,235 (10.0)
 1,596 (10.4)
Region
Alentejo 1,280 (10.4) 752 (4.9)
Algarve 325 (2.6) 487 (3.2)
Centro 1,401 (11.4) 972 (6.3)
Lisboa e Vale do Tejo 1,462 (11.9) 3,396 (22.1)
Norte
 7,838 (63.7)
 9,789 (63.6)
Epidemiologic week of diagnosis, 2022
Week 17 980 (8.0) 4,200 (27.3)
Week 18 3,237 (26.3) 5,691 (37.0)
Week 19 5,655 (46.0) 4,763 (30.9)
Week 20 1,080 (8.8) 492 (3.2)
Week 21 799 (6.5) 174 (1.1)
Week 22 348 (2.8) 56 (0.4)
Week 23
 207 (1.7)
 20 (0.1)
COVID-19 vaccination status
Not vaccinated 590 (4.8) 631 (4.1)
Complete primary vaccination 2,530 (20.6) 2,434 (15.8)
First booster vaccination
 9,186 (74.7)
 12,331 (80.1)
Previous SARS-CoV-2 infection
No 11,073 (90.0) 14,536 (94.4)
Yes
 1,233 (10.0)
 860 (5.6)
Hospitalization
No 12,254 (99.6) 15,342 (99.7)
Yes 52 (0.4)
 54 (0.4)

Main Article

1These first authors contributed equally to this article.

2These authors contributed equally to this article.

Page created: December 31, 2022
Page updated: February 19, 2023
Page reviewed: February 19, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external